The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed/refractory b-cell non-Hodgkin lymphoma: A comparison with non-Japanese DCS4968g study.
 
Kiyohiko Hatake
Honoraria - Kyowa Hakko Kirin; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Meiji Seika Kaisha; Otsuka
Research Funding - Abbvie; Bayer; Bristol-Myers Squibb; Celgene; Chugai Pharma; Eisai; Gilead Sciences; Janssen; Kyowa Hakko Kirin; Novartis; Ono Pharmaceutical; Takeda
 
Tomohiro Kinoshita
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
 
Yasuhito Terui
No Relationships to Disclose
 
Masahiro Yokoyama
Consulting or Advisory Role - Chugai Pharma
 
Dai Maruyama
Honoraria - Celgene; Chugai Pharma; Eisai; Fujifilm; Janssen; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Mundipharma; Nihonkayaku; Ono Pharmaceutical; Sanofi; Takeda
 
Shinichi Makita
Honoraria - Chugai Pharma
 
Kazuhito Yamamoto
Honoraria - ARIAD; Bristol-Myers Squibb; Celgene; Janssen; Kyowa Hakko Kirin; Ono Pharmaceutical; Pfizer; Sumitomo Dainippon; Takeda
Consulting or Advisory Role - Novartis; Otsuka
Research Funding - Abbvie (Inst); ARIAD (Inst); Celgene (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Yusuke Higuchi
No Relationships to Disclose
 
Satsuki Murakami
Speakers' Bureau - Pfizer
 
Akiko Uechi
Employment - Chugai Pharma
 
Yoshimasa Ishida
Employment - Chugai Pharma
 
Jamie H. Hirata
Employment - Genentech
 
Kensei Tobinai
Honoraria - Eisai; Mundipharma; Spectrum Pharmaceuticals; Takeda; Zenyaku Kogyo
Research Funding - Abbvie (Inst); Celgene (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Mundipharma (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Takeda (Inst)